Current Report Filing (8-k)
June 06 2019 - 7:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 6, 2019
ATHENEX, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-38112
|
|
43-1985966
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
1001 Main Street, Suite 600, Buffalo, New York
|
|
14203
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (716)
427-2950
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Securities registered pursuant to Section 12(b) of the Exchange Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.001 per share
|
|
ATNX
|
|
The Nasdaq Global Select Market
|
On June 6, 2019, Athenex, Inc. (the Company) issued a press release to announce preliminary positive clinical activity signals in a Phase I
clinical trial of
KX2-391,
or tirbanibulin, for the treatment of psoriasis. Also on June 6, 2019, the Company issued a press release to announce that it has voluntarily temporarily suspended production
activities at its active pharmaceutical ingredient plant in Chongqing, China. These press releases are filed as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form
8-K.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
ATHENEX, INC.
|
|
|
Date: June 6, 2019
|
|
/s/ Randoll Sze
|
|
|
Name:
|
|
Randoll Sze
|
|
|
Title:
|
|
Chief Financial Officer
|
2
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Sep 2023 to Sep 2024